Searchable abstracts of presentations at key conferences in endocrinology

ea0059ep69 | Neoplasia, cancer & late effects | SFEBES2018

An unusual case of hypoglycaemia

Bruce Peter Przylecki , Majeed Muhammad Shakeel , Till David , Deore Mahesh

A 79-year-old female patient, with a background history of hypertension and ischaemic heart disease was brought by ambulance to hospital with near collapse episode associated with capillary blood glucose (CBG) of 2.1 mmol/l. Her regular medications include Ramipril, clopidogrel and atorvastatin. She had no history of diabetes. While inpatient, it was observed that majority of low capillary blood glucose readings (CBG) were late night or early mornings. At venous glucose of 1.9...

ea0038p67 | Clinical practice/governance and case reports | SFEBES2015

IgG4-related hypophysitis: a novel candidate to the hypophysitis spectrum

Vyas Shemin S , Yahia Seifeldin , Lanyon Peter , Page Simon

A 57-year-old gentleman presented with bilateral painless submandibular swelling, and flu like symptoms. A biopsy from the enlarged submandibular gland showed chronic sclerosing sialadenitis with lymphocytic infiltration. Immunohistochemistry showed plasma cells positive for CD79a and IgG4, and a combination of CD4 and CD8 positive lymphocytes. IgG4 levels were significantly raised (3.16 g/l, NR <1.3 g/l). A diagnosis of IgG4 syndrome was made. Chest and abdominal CT imagi...

ea0038p82 | Clinical practice/governance and case reports | SFEBES2015

Should all short Synacthen tests be agreed by an endocrine team?

Jarvis Peter , Page Georgina , Holt Helen , Richardson Tristan , Partridge Helen

Background: Short Synacthen tests (SSTs) are used to assess adrenal function by injecting tetracosactide and measuring blood cortisol after 30 and 60 min. Many SSTs at Royal Bournemouth Hospital (RBH) are undertaken externally to the Bournemouth Diabetes and Endocrine Centre (BDEC). There is an increasing cost-implication for undertaking SSTs exacerbated by recent problems with Synacthen supply. A 0900 h cortisol or random cortisol on acutely unwell patients can be sufficient ...

ea0038p97 | Clinical practice/governance and case reports | SFEBES2015

Accuracy of sample timing with short Synacthen tests at Royal Bournemouth Hospital

Jarvis Peter , Page Georgina , Holt Helen , Richardson Tristan , Partridge Helen

Background: Short Synacthen tests (SSTs) are used to assess adrenal function by injecting tetracosactide and measuring blood cortisol after 30 and 60 min. Accuracy of timing helps enable successful interpretation of results. A SST is an invasive test although it is normally well tolerated. There is an increasing cost-implication for undertaking SSTs exacerbated by recent problems with Synacthen supply.Method: We undertook a retrospective audit of 333 pat...

ea0038p115 | Clinical practice/governance and case reports | SFEBES2015

Audit of adult GH replacement therapy in Nottingham

Seetho Ian , Chee Carolyn , Mansell Peter , Page Simon

Introduction: Guidelines for the use of GH in GH deficient adults were issued by the UK National Institute for Clinical Excellence (NICE). To assess current practice in relation to these guidelines, a review of patients receiving GH treatment was performed. The aims were to i) assess if adults with GH deficiency met NICE criteria for GH therapy and ii) identify reasons for initiating or continuing GH treatment if NICE criteria were not met.Methods: Retro...

ea0038p154 | Neoplasia, cancer and late effects | SFEBES2015

Adrenal pigmentation in PPNAD is a result of melanin deposition and associated with upregulation of the melanocortin 1 receptor

Cavlan Dominic , Storr Helen , Berney Dan , Evagora Chris , King Peter

Primary pigmented nodular adrenal disease (PPNAD) is a form of bilateral adrenocortical hyperplasia characterised by small to normal sized adrenal glands containing multiple small cortical pigmented nodules1. It may occur independently, but 90% of cases are a manifestation of the Carney complex. Most cases of PPNAD are diagnosed before age 30, and are the result of a germline mutation in PRKAR1A or PDE11A, leading to upregulation of cAMP signalling. It is a cause of...

ea0038p347 | Reproduction | SFEBES2015

Analysis of the human foetal gonadal proteome at 13–14 weeks of gestation

Matthews Rebecca , Filis Panagiotis , O'Shaughnessy Peter , Fowler Paul

Introduction: The human masculinisation programming window (8–14 weeks of gestation) sees testis-derived androgen drive the foetus towards a male phenotype. However, there are few systematic studies of human foetal gonad development.Aim: To conduct a pilot analysis of the foetal gonadal proteome at the end of the masculinisation programming window (13–14 weeks of gestation).Methods: Twenty-eight electively terminated foet...

ea0037gp.21.05 | Pituitary – Diagnosis of Cushing's disease | ECE2015

Mental fatigue and executive dysfunction in patients with Cushing's syndrome in remission

Papakokkinou Eleni , Berglund Peter , Johansson Birgitta , Ragnarsson Oskar

Background: Patients with Cushing’s syndrome (CS) in remission often suffer from impaired quality of life and cognitive dysfunction. Mental fatigue is characterized by mental exhaustion which appears especially during sensory stimulation or following mentally strenuous tasks. Other typical features are long recovery time for restoration of mental energy, irritability, impaired memory and concentration and sensitivity to stress, light and noise. The primary aim of this stu...

ea0037ep636 | Obesity and cardiovascular endocrinology | ECE2015

The use of intermittent 7.5 mg tolvaptan on an out-patient basis for SIADH: a retrospective audit from a tertiary cancer hospital

Kumar Mohit , Pichaipillai Lakshminarayanan , Trainer Peter , Higham Claire

Tolvaptan (a V2 receptor antagonist) is licensed for correction of hyponatraemia in patients with SIADH at an initial dose of 15 mg od. Data in oncology patients with SIADH suggest 7.5 mg can safely and effectively increase sodium levels where 15 mg can on occasion lead to too rapid a correction. Recommendations suggest a repeat sodium taken at 4–6 h. We retrospectively assessed the safety and efficacy of intermittent out-patient dosing with 7.5 mg tolv...

ea0037ep731 | Pituitary: clinical | ECE2015

Carney complex – a case report

Urbankova Helena , Kulich Michal , Veteskova Elena , Vanuga Peter

Carney complex (CNC) is rare autosomal dominant disorder, which was firstly described as a combination of manifestation of myxomas, spotty skin pigmentation and endocrine overactivity in 1985. This condition affects many organs and varies in clinical manifestation. The presence of at least two clinical signs is considered as pathognomonic with regard to a sporadic form of CNC, and an evidence of at least one sign with simultaneous manifestation of CNC in any of first degree re...